Here is Why CRISPR Therapeutics (CRSP) Appears so Good

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is recognized as one of the 10 most shorted biotech stocks to consider for investment by hedge funds [1] - Morgan Stanley raised its price target for CRISPR Therapeutics from $32 to $33 while maintaining an Underweight rating [1] - Needham increased its price target from $80 to $82, maintaining a Buy rating, indicating over 45% upside potential [2] Financial Performance - Casgevy, a therapy developed by CRISPR's partner Vertex Pharmaceuticals, generated $116 million in sales in 2025, exceeding the previous target of approximately $100 million [2] - The strong sales performance of Casgevy indicates early commercial traction and supports a positive outlook for CRISPR Therapeutics [2] Company Overview - CRISPR Therapeutics is a gene editing company focused on developing potentially curative medicines for serious diseases, including sickle cell disease and blood disorders [3] - The company's broader pipeline also addresses cancer, autoimmune conditions, and diabetes, positioning it as a leader in the future of genetic medicine [3]